Which stocks to look for in China Shipping Pharmaceutical and Health Industry
Are you also looking for information on which stocks to look for in China Shipping Pharmaceutical and Health Industry, that's right, I've carefully compiled this China Shipping Pharmaceutical and Health Industry Which Stocks To Look For article, which should be able to answer your questions, and more information related to which stocks to look for in China Shipping Pharmaceutical and Health Industry can be found by searching in the upper right corner.
Which stocks to look for in China Sea pharmaceutical and health industry
Chinese Sea pharmaceutical and health industry is currently involved in the following two stocks:
__ Baiyunshan (600332): Baiyunshan is a listed company under the Guangzhou Pharmaceutical Group, which is China's first to obtain a license for drug clinical trials of new drug research and development institutions enterprise.
__China Pharmaceuticals (600056): The company is one of the core platforms of China's pharmaceutical and healthcare industry, mainly engaged in chemical drugs, domestic pharmaceutical distribution business, as well as containing derivative business.
It is recommended that you decide on your investment strategy based on your investment objectives, risk tolerance and market conditions. The evaluation results of the above stocks are for reference only, and specific investment decisions need to be made based on professional investment advice and industry analysis.
China Pharmaceuticals Stock Analysis
China Pharmaceuticals (01202.HK) is a company primarily engaged in the pharmaceutical manufacturing business. The company recently announced its 2022 financial results, reporting full-year operating revenue of $1.037 billion, up 5.95% year-over-year. However, net profit attributable to shareholders of the listed company amounted to 291 million yuan, a year-on-year decline of 14.24 percent. The company mentioned that this was due to the group's implementation of convertible bond share buybacks and cash dividends in 2021, totaling 147 million yuan, as well as exchange losses of 45.419 million yuan from exchange rate fluctuations during the period.
However, in terms of business segments, as the company continued to expand its sales channels for its own-branded products during the reporting period, the operating income of its pharmaceutical manufacturing business amounted to 831 million yuan, a year-on-year increase of 17.67 percent, with a gross profit margin of 63.05 percent, an increase of 4.78 percent percentage points from the same period of the previous year. This reflects an improvement in the company's main business.
In terms of Hong Kong's pharmaceutical sector trends, the sector is down an average of 14% over the past year to April 9, 2023, reflecting potentially volatile conditions across the industry. However, at the same time, if you subtract the average industry decline over the same period from the share price of CNH Pharmaceuticals, you'll see that CNH Pharmaceuticals has outperformed the broader market (by 3.73%), which could have a positive impact on the company's investment value.
To summarize, although China Shipping Pharmaceutical's financial performance in FY2022 is weaker than expected, its improvement in business segments and relatively strong market performance may give investors optimistic expectations for its future growth.
How is the stock quote of China Shipping Pharmaceutical
The stock code of China Shipping Pharmaceutical is 001224, and the current share price is 14.610. As far as I know, China Shipping Pharmaceutical is an innovative pharmaceutical and healthcare industrial group integrating pharmaceutical research and development, pharmaceutical industry, pharmaceutical business and healthcare. The company's highlight is that it has the leading R&D capability in chemical, biological and traditional Chinese medicine in China, and possesses the whole drug R&D capability from R&D of innovative drugs, pharmacy research, clinical trials to marketing and sales.
In addition, Zhonghai Pharmaceutical's pharmaceutical dosage forms are mainly oral solid dosage forms, and it has four major dosage forms: large-volume injections, lyophilized powder injections, inhalation solutions, and API combinations. Its three major clinical departments are cardiovascular medicine, orthopedics and neurology, and it has dozens of domestic exclusive agent distribution varieties. Commercial retail terminals cover 2.57 million retail pharmacies and 130,000 retail clinics nationwide. The company's pharmaceutical wholesale business covers 29 provinces, autonomous regions and municipalities directly under the central government, with more than 31,000 hospitals in cooperation and annual terminal sales of more than 40 billion yuan.
In summary, China Shipping Pharmaceutical is a competitive company in the pharmaceutical and health industry. For the company's stock quote, you need to pay further attention to the market dynamics and company announcements.
China Pharmaceuticals Mixed Stock
China Pharmaceuticals Mixed Stock Securities Investment Fund is a mixed-type fund financial product issued by China Shipping Fund.
The investment objective of the fund: the fund mainly invests in pharmaceutical and biological, health industry and health-related high-quality non-medical stocks, and through asset allocation and flexible use of various investment strategies, to grasp the capital appreciation and relatively stable cash income, and to realize the long-term and stable appreciation of the fund's assets.
What stocks are included in China Shipping Pharmaceutical Mixed Fund
China Shipping Pharmaceutical Mixed Fund*** has ____11 ____ which 11 funds*** track ____5 ____ indices, namely A-share Mixed Index, A-share Pharmaceutical and Healthcare Index, A-share Healthcare Index, A-share Medical Equipment and Services Index, and the A-share Biomedical Index.
These funds invest primarily in stocks in the pharmaceutical and biotechnology, medical device, medical service, chemical pharmaceutical and medical equipment industries, as well as some stocks of non-pharmaceutical companies. The performance benchmarks of these funds are CSI Pharmaceutical and Healthcare Industry Index return __70% + China Total Bond Index (full price) return __20% + Financial Institutions Renminbi Call Deposit Rate (after tax) __10%.
Please note that investment involves risks and specific investment strategies may vary depending on the fund's particular circumstances. Before making any investment decision, you are advised to read carefully the information in the prospectus and fund contract of the relevant fund.
That's all for the introduction of which stocks to look for in China Sea Pharmaceutical and Health Industry.